What is Turner syndrome?
Turner syndrome (TS) is a chromosomal condition that describes girls and women with common features that are caused by complete or partial absence of the second sex chromosome. The syndrome is named after Dr. Henry Turner, who was among the first to describe its features in the 1930's. TS occurs in approximately 1 of 2,000 female's born and in as many as 10% of all miscarriages.
How is Turner syndrome diagnosed?
Diagnosis is made through a test called a karyotype, which is usually performed on cells in the amniotic fluid before birth and on cells in the blood after birth. A trained specialist counts the chromosomes in the white blood cells and looks for abnormalities. Females normally have two X chromosomes (46,XX) and males have one X and one Y (46,XY). Turner syndrome individuals are missing all or part of one of their sex chromosomes. About half of girls with Turner syndrome have only one X chromosome (45,X). Another third have two X chromosomes, but part of one X is missing. Other individuals with Turner syndrome have a mosaic pattern: some of their cells are missing an X chromosome (45,X), while other cells have different chromosome composition (such as 46,XX)
Turner syndrome may be diagnosed throughout the life span, including adulthood, if signs are subtle. Signs that indicate a karyotype is needed can include:
What are the primary characteristics of Turner syndrome?
The most common feature of Turner syndrome is short stature. The average height of an adult TS woman who has not received human growth hormone treatment is 4’8”. Individuals tend to be a little shorter at birth, averaging 18.5” compared to an average of 20” for all girls. Growth failure continues after birth, and most girls with TS fall below the normal female growth curve for height during early childhood. TS girls who are not treated with hormone replacement usually do not have a pubertal growth spurt; many will continue to grow at a slow rate until they are in their twenties. Many girls who undergo growth hormone treatment have been able to achieve adult height within the lower range of normal.
Premature ovarian failure
Most (90%) TS individuals will experience early ovarian failure. In the general population, the ovaries produce eggs and hormones necessary for the development of secondary sexual characteristics. Estrogen replacement therapy is necessary for breast development, feminine body contours, menstruation and proper bone development. About a third of TS individuals will show some signs of breast development without estrogen treatment; however, many will not complete puberty, and those that do often have premature ovarian failure. Therefore, the majority of individuals will require estrogen from puberty until the normal age of menopause. Fertility without assisted reproduction therapy is rare (less than 1%).
Many characteristic features are associated with Turner syndrome. Their presence and severity vary greatly from individual to individual.
What are the associated risks with Turner syndrome?
Several medical problems occur more frequently in individuals with Turner syndrome than in the general population. It is important that TS individuals are screened regularly to see if any of these problems exist. Most of these conditions can be managed successfully with good medical care.
How can Turner Syndrome be treated?
The treatment of TS individuals should be individualized; physicians, family and patients should decide on treatment options together.
Growth Hormone Therapy
Human growth hormone (hGH) is an FDA-approved drug used to increase the growth rate and achieve greater final height in TS patients. Therapy should be considered when a TS individual experiences growth failure and/or drops below the 5th percentile of the normal female growth curve. The expected increase in height depends upon many factors, including how early GH is started, what dose is given, the duration of treatment, if anabolic steroids (such as oxandrolone) are also given, and how late estrogen therapy is begun. Gains in height between 5 and 16 cm (2 and 6 inches) have recently been reported; however, not every individual responds to growth hormone. Treatment is discontinued when growth is very slow(less than 2 cm or 1 inch per year) or if the patient has reached a satisfactory height.
This therapy is necessary in most TS individuals because of ovarian failure. Therapy is typically started at 12-14 years of age but should be individualized to optimize both growth and pubertal development. Estrogen is given in small doses to initiate puberty and breast development. The dose is then increased and progesterone is added in order to initiate a monthly menstrual cycle. TS individuals can experience normal sexual function on estrogen therapy. Because of the role estrogen plays in maintaining healthy bone mass, it is generally recommended that the therapy continue until the age of normal menopause (approximately 50 years of age).
Com a colaboração: Turner Syndrome Societyhttp://www.turnersyndrome.org/